Published in J Surg Oncol on May 01, 2004
Primary psoas sarcoma causing malignant psoas syndrome: favourable response to radiotherapy. Ann Transl Med (2017) 0.75
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Soft-tissue sarcomas in adults. N Engl J Med (2005) 5.97
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst (2007) 4.46
Excision margins in high-risk malignant melanoma. N Engl J Med (2004) 3.94
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2008) 2.06
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol (2004) 1.89
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst (2011) 1.45
Retroperitoneal tumours: review of management. Ann R Coll Surg Engl (2011) 1.42
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr (2011) 1.34
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat (2009) 1.29
Does the two-week rule pathway improve the diagnosis of soft tissue sarcoma? A retrospective review of referral patterns and outcomes over five years in a regional sarcoma centre. Ann R Coll Surg Engl (2010) 1.28
Aggressive fibromatosis: MRI features with pathologic correlation. AJR Am J Roentgenol (2006) 1.23
Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol (2004) 1.19
A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Res (2004) 1.18
Transmission of donor melanoma by organ transplantation. Lancet Oncol (2010) 1.15
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol (2011) 1.14
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res (2006) 1.14
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol (2013) 1.12
Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol (2010) 1.12
Adult rhabdomyosarcoma: cross-sectional imaging findings including histopathologic correlation. AJR Am J Roentgenol (2007) 1.12
The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol (2005) 1.10
Long-term results in elderly patients with differentiated thyroid carcinoma. Cancer (2003) 1.06
Who would have thought a single Ki67 measurement would predict long-term outcome? Breast Cancer Res (2009) 1.04
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol (2002) 1.04
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast Cancer Res Treat (2012) 1.00
Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int (2005) 0.99
Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer (2005) 0.99
Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. Radiother Oncol (2011) 0.98
Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev (2002) 0.97
Malignancies confined to disused arteriovenous fistulae in renal transplant patients: an important differential diagnosis. Am J Nephrol (2011) 0.97
The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica (2004) 0.96
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J (2004) 0.96
Amputation for soft-tissue sarcoma. Lancet Oncol (2003) 0.95
Ilioinguinal lymph node dissection for palpable metastatic melanoma to the groin. ANZ J Surg (2008) 0.95
Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol (2007) 0.95
The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell Melanoma Res (2014) 0.95
Intratumoral estrogen disposition in breast cancer. Clin Cancer Res (2010) 0.95
Autonomic nerve trauma at radical hysterectomy: the nerve content and subtypes within the superficial and deep uterosacral ligaments. Reprod Sci (2008) 0.94
The radiological manifestations of intramuscular haemangiomas in adults: magnetic resonance imaging, computed tomography and ultrasound appearances. Skeletal Radiol (2007) 0.93
A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol (2007) 0.92
What does the medical profession mean by "standard of care?". J Clin Oncol (2009) 0.91
Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Res Treat (2010) 0.91
Sentinel lymph node biopsy in malignant melanoma. BMJ (2008) 0.91
Gastric necrosis in a patient with bulimia. Eur J Surg (2002) 0.91
Intra-abdominal metastases from soft tissue sarcoma. J Surg Oncol (2004) 0.90
A quality-of-life study in high-risk (thickness > = or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc (2004) 0.89
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res (2012) 0.89
Sentinel lymph node biopsy: not yet standard of care for melanoma. BMJ (2004) 0.89
Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy. Radiother Oncol (2010) 0.88
Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology (2013) 0.88
Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol (2010) 0.88
Immediate breast reconstruction using biodimensional anatomical permanent expander implants: a prospective analysis of outcome and patient satisfaction. Plast Reconstr Surg (2003) 0.87
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. Breast Cancer Res (2012) 0.87
Freedom of expression or protectionism in the debate on sentinel node biopsy in melanoma. J Am Acad Dermatol (2009) 0.87
Prognostic false-positivity and cost-effectiveness in sentinel node biopsy in melanoma. Ann Surg Oncol (2009) 0.87
Sentinel-node biopsy in melanoma. N Engl J Med (2014) 0.87
Management of benign retroperitoneal schwannomas: a single-center experience. Am J Surg (2011) 0.86
Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? J Clin Oncol (2003) 0.85
Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast (2002) 0.85
Portsite recurrence after laparoscopy for staging of retroperitoneal sarcoma. Surg Laparosc Endosc Percutan Tech (2003) 0.84
Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. Breast Cancer Res Treat (2013) 0.83
DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy. Radiat Environ Biophys (2014) 0.83
Correlation of in vitro lymphocyte radiosensitivity and gene expression with late normal tissue reactions following curative radiotherapy for breast cancer. Radiother Oncol (2012) 0.82
Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. Clin Adv Hematol Oncol (2007) 0.82
Where is the evidence base for benefits of sentinel node biopsy in melanoma? BMJ (2013) 0.79
Angiosarcoma developing in a non-functioning arteriovenous fistula post-renal transplant. J Surg Oncol (2010) 0.79
Sentinel-node biopsy in melanoma. N Engl J Med (2007) 0.78
Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. Clin Cancer Res (2010) 0.78
Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model. Cancer Res (2003) 0.78
Intraoperative radiotherapy for early breast cancer. Lancet (2010) 0.78
Synchronous mantle cell lymphoma, chronic lymphocytic leukaemia and melanoma in a single lymph node. Acta Haematol (2010) 0.78
Prostate-specific antigen in nipple aspiration fluid: menstrual cycle variability and correlation with serum prostate-specific antigen. Tumour Biol (2003) 0.77
Evaluation of outcome after immediate breast reconstruction: prospective comparison of four methods. Plast Reconstr Surg (2005) 0.77
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 0.77
Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines. Fam Cancer (2008) 0.77
Manually after-loaded 192Ir low-dose rate brachytherapy after subtotal excision and flap reconstruction of recurrent cervical lymphadenopathy from head and neck cancer. Radiother Oncol (2006) 0.76
The Million Women Study and breast cancer. J Br Menopause Soc (2003) 0.76
Sydney Melanoma Unit patients in breach of multicentre selective lymphadenectomy trial protocol? ANZ J Surg (2006) 0.75
Are there guidance issues relating to sentinel node biopsy for melanoma in the UK? Br J Plast Surg (2004) 0.75
Lymphoedema in the observation and biopsy arms of MSLT-1. Ann Surg Oncol (2011) 0.75
Dermatologists should exert a greater influence over sentinel lymph node biopsy for melanoma in the U.K. Br J Dermatol (2005) 0.75
Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med (2011) 0.75
Cure of cutaneous melanoma. BMJ (2006) 0.75
Time for comprehensive reporting of MSLT-I. Lancet Oncol (2006) 0.75
Dr. Herbert Lumley Snow, MD, MRCS (1847-1930): the original champion of elective lymph node dissection in melanoma. Ann Surg Oncol (2004) 0.75
False-positivity in the sentinel lymph nodes in melanoma and breast cancer. Cancer (2010) 0.75
Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma (Br J Surg 2007; 94: 1293-1299). Br J Surg (2008) 0.75
Some of the 2009 American Joint Committee on Cancer melanoma staging and classification is not evidence based. J Clin Oncol (2010) 0.75
More breast cancer findings from the Women's Health Initiative. J Br Menopause Soc (2003) 0.75
Expectoration of endobronchial sarcoma metastasis. ANZ J Surg (2004) 0.75
Le Fort I osteotomy and low-dose rate Ir192 brachytherapy for treatment of recurrent nasopharyngeal tumours. Radiother Oncol (2003) 0.75
Progestogens and breast cancer risk: the role of hormonal contraceptives and hormone replacement therapy. J Fam Plann Reprod Health Care (2003) 0.75